rac-(1S,5R)-2-oxa-4-azabicyclo[3.2.0]heptan-3-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧氮杂卓类
• 英文名称: rac-(1S,5R)-2-oxa-4-azabicyclo[3.2.0]heptan-3-one
• 英文别名: rac-(1R,5S)-2-oxa-4-azabicyclo[3.2.0]heptan-3-one；(1S,5R)-2-oxa-4-azabicyclo[3.2.0]heptan-3-one
• 化学式: C₅H₇NO₂
• 分子量: 113.116
• InChiKey: SWPHEDFPEADJIA-DMTCNVIQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(6-chloropyrazin-2-yl)-3-dimethyl-6-(2-methylpyrimidin-5-yl)indolin-2-one 、 rac-(1S,5R)-2-oxa-4-azabicyclo[3.2.0]heptan-3-one 在 copper(l) iodide 、 potassium carbonate 、 N,N'-二甲基乙二胺 作用下， 以 乙腈 为溶剂， 反应 24.0h， 以19%的产率得到rac-(1S,5R)-4-(6-(3,3-dimethyl-6-(2-methylpyrimidin-5-yl)-2-oxoindolin-1-yl)pyrazin-2-yl)-2-oxa-4-azabicyclo[3.2.0]heptan-3-one
  参考文献：
  名称：

  [EN] INDOLIN-2-ONE DERIVATIVES
  [FR] DÉRIVÉS D'INDOLIN-2-ONE

  摘要：

  本发明涉及一般式(I)的吲哚啉-2-酮衍生物，其中取代基如权利要求书中所定义。这些化合物可用于治疗与精神分裂症的阳性（精神病）和阴性症状、物质滥用、酒精和药物成瘾、强迫症障碍、认知障碍、双相障碍、情绪障碍、重度抑郁症、治疗抗性抑郁症、焦虑障碍、阿尔茨海默病、自闭症、帕金森病、慢性疼痛、边缘人格障碍、神经退行性疾病、睡眠障碍、慢性疲劳综合症、僵硬、炎症性疾病、哮喘、亨廷顿病、注意力缺陷多动障碍、肌萎缩侧索硬化、关节炎、自身免疫疾病、病毒和真菌感染、心血管疾病、眼科学和炎症性视网膜疾病以及平衡问题、癫痫和伴有癫痫的神经发育障碍相关的中枢神经系统疾病的治疗。

  公开号：

  WO2017076842A1
• 作为产物：
  描述：

  N,N'-羰基二咪唑 、 2-Aminocyclobutan-1-ol 以 四氢呋喃 为溶剂， 生成 rac-(1S,5R)-2-oxa-4-azabicyclo[3.2.0]heptan-3-one
  参考文献：
  名称：

  PRMT5 INHIBITORS AND USES THEREOF

  摘要：

  The present disclosure relates generally to compounds that inhibit PRMT5. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through inhibiting PRMT5. The disclosure further relates to the use of the compounds for the treatment of a disease or condition associated with chromosome 9p21 deletion or MTAP null. The disclosure further relates to the use of the compounds for the treatment of cancers.

  公开号：

  WO2024137852A1

文献信息

• [EN] INDOLIN-2-ONE DERIVATIVES<br/>[FR] DÉRIVÉS D'INDOLIN-2-ONE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2017076842A1

  公开（公告）日：2017-05-11

  The present invention is concerned with indolin-2-one derivatives of general formula (I) wherein the substituents are defined in claim 1. The compounds may be used in the treatment of CNS diseases related to positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, Alzheimer's disease, autism, Parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disturbances, chronic fatigue syndrome, stiffness, inflammatory disease, asthma, Huntington's disease, ADHD, amyotrophic lateral sclerosis, effects in arthritis, autoimmune disease, viral and fungal infections, cardiovascular diseases, ophthalmology and inflammatory retinal diseases and balance problems, epilepsy and neurodevelopmental disorders with co-morbid epilepsy.

  本发明涉及一般式(I)的吲哚啉-2-酮衍生物，其中取代基如权利要求书中所定义。这些化合物可用于治疗与精神分裂症的阳性（精神病）和阴性症状、物质滥用、酒精和药物成瘾、强迫症障碍、认知障碍、双相障碍、情绪障碍、重度抑郁症、治疗抗性抑郁症、焦虑障碍、阿尔茨海默病、自闭症、帕金森病、慢性疼痛、边缘人格障碍、神经退行性疾病、睡眠障碍、慢性疲劳综合症、僵硬、炎症性疾病、哮喘、亨廷顿病、注意力缺陷多动障碍、肌萎缩侧索硬化、关节炎、自身免疫疾病、病毒和真菌感染、心血管疾病、眼科学和炎症性视网膜疾病以及平衡问题、癫痫和伴有癫痫的神经发育障碍相关的中枢神经系统疾病的治疗。
• PRMT5 INHIBITORS AND USES THEREOF
  申请人：[en]GILEAD SCIENCES, INC.

  公开号：WO2024137852A1

  公开（公告）日：2024-06-27

  The present disclosure relates generally to compounds that inhibit PRMT5. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through inhibiting PRMT5. The disclosure further relates to the use of the compounds for the treatment of a disease or condition associated with chromosome 9p21 deletion or MTAP null. The disclosure further relates to the use of the compounds for the treatment of cancers.